CureVac N.V. (CVAC)
| Market Cap | 18.28B |
| Revenue (ttm) | 17.38M |
| Net Income (ttm) | -102.42M |
| Shares Out | 176.46M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | 11.45 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $102.69 |
| Previous Close | $101.07 |
| Change ($) | 1.62 |
| Change (%) | 1.60% |
| Day's Open | 100.05 |
| Day's Range | 99.11 - 103.25 |
| Day's Volume | 230,420 |
| 52-Week Range | 43.80 - 136.27 |
CureVac shares currently trade at $100.6 - down from nearly $150 in early December. The mRNA specialist IPO'd at a price of just $16 in August last year, but shares have spiked in anticipation...
CureVac partners with Bayer to accelerate vaccine production
Franz-Werner Haas, CureVac CEO says it has initiated a phase 2b-3 trial and expects to enroll 35,000 people in Europe and Latin America. He joins 'Closing Bell' to discuss.
Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protec...
CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.
The coronavirus vaccine developer announced a new partnership with a major player on the global pharmaceutical scene.
Sometimes you need a little help from a big brother.
CureVac BV (NASDAQ: CVAC) shares have received a nice lift and breached the $100 level for the first time in the new year. What Happened: German coronavirus vaccine maker CureVac said Thursday...
The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.
LOS ANGELES--(BUSINESS WIRE)---- $CVAC #COVID19--Investor's Business Daily (IBD), a leading financial news and research organization, today announced its list of the 100 Best Companies of 2020...
Companies enter into a collaboration and services agreement Bayer to support CureVac in numerous areas, including development and supply of CVnCoV CureVac benefits from Bayer's expertise and e...
German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two compani...
German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild repo...
Study to assess safety and immunogenicity of CVnCoV in high-risk population group Study builds on observational epidemiological study TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 2...
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.
CureVac N.V. (NASDAQ: CVAC) advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study.
Tübingen-based CureVac said the Phase 3 trial will include more than 35,000 volunteers in Europe and Latin America
If we judge by return on investment, these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race.
Here's what you need to know about all of the leaders in the coronavirus vaccine race.
And it's not too far behind coronavirus vaccine leaders Pfizer and Moderna.
The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in ...
Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO
Nov.18 -- CureVac Chief Executive Officer Franz-Werner Haas discusses the progress on the biopharmaceutical company's Covid-19 vaccine and scale-up for its production on “Bloomberg Surveillance.”
CureVac expects to announce partnerships with vaccine developers and manufacturers in coming weeks to ramp up capacity of its potential vaccine candidate.
Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.
Biotech is on every investor's mind as we move closer and closer to a successful vaccine for the coronavirus. Here are three contenders for your portfolio.
German biopharma CureVac BV (NASDAQ: CVAC) — which is developing an mRNA vaccine against the novel coronavirus — was rallying Tuesday following the release of detailed interim Phase 1 data fo...
Shares of CureVac gained 8.0% in premarket trading on Tuesday after the company disclosed additional clinical data about how its COVID-19 vaccine candidate is performing in a Phase 1 clinical ...
Participants in the phase 1 clinical trial mounted an immune response after being inoculated with CVnCoV.
Recent hot IPO CureVac reported positive Phase 1 clinical trials data for its Covid-19 vaccine candidate, which is among a number based on mRNA technology. CVAC stock rose on the news.
German biotech CureVac said advanced clinical trials are on track to launch by the end of 2020.
The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.
CureVac is using the same messenger RNA approach that Moderna uses. Why is Moderna getting all the headlines?
There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.
In the race for a vaccine, a pause in progress sets you back.
These companies made an early splash, but that doesn't mean they're a safe choice for investors.
CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.
CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.
Regeneron Pharmaceuticals stock rose on positive data on its possible Covid-19 treatment, while shares of Moderna and CureVac stock rose as their possible Covid-19 vaccines made advances. The ...
CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?
These two stocks have made shareholders rich in a very short amount of time. Here's why new potential investors should stay away.
BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.
Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. AstraZeneca (NYSE:AZN) CureVac (NASDAQ:CVAC) GlaxoSmithKline (NYSE:G...
With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.
Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.
Investors should exercise caution before buying into these high-flying growth stocks.
CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.
Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?
Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.
That money will also be used for its production.
Recent IPO and vaccine play CureVac stock could bounce back – but tread carefully. Much of the upside remains priced into shares.
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's pa... [Read more...]
| Industry Biotechnology | IPO Date Aug 14, 2020 |
| CEO Dr. Franz-Werner Haas L.L.M., Ph.D., LL.M. | Employees 500 |
| Stock Exchange NASDAQ | Ticker Symbol CVAC |
Financial Performance
In 2019, CureVac's revenue was $17.42 million, an increase of 35.31% compared to the previous year's $12.87 million. Losses were -$99.87 million, 40.2% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for CureVac stock is "Buy." The 12-month stock price forecast is 73.36, which is a decrease of -28.56% from the latest price.